A novel trp2 isoform containing hla-a2 restricted cytotoxic t lymphocyte epitopes
CA 2441225 C · Owner: Khong, Hung · Inventors: Rosenberg, Steven A.; Khong, Hung
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a new and potent tumor antigen capable of causing T cells to elicit an immune response and methods of its use in the detection, prevention, and treatment of cancer preferably melanoma, in , mammals. More specifically this invention relates to the identification of a novel tyrosinase-related protein 2 (TRP2) specifically TRP2-6b protein, and , peptides derived from said protein. The present invention therefore also relates to nucleic acid sequences that encode the TRP2-6b protein or peptide fragments thereof.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 15, 2002 and granted July 26, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 15, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 15, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.